Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Camila L P A M Bezerra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: COVID-19, Sepsis, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Our aim in this retrospective cohort study was to assess the impact on mortality of the empirical use of polymyxin as therapy for carbapenem-resistant gram-negative bacteria (CR-GNB) in septic patients. The study was performed at a tertiary academic hospital in Brazil, from January 2018 to January 2020, the pre–coronavirus disease 2019 period.
Methods
We included 203 patients with suspected sepsis. The first doses of antibiotics were prescribed from a “sepsis antibiotic kit”, which contained a selection of drugs, including polymyxin, with no preapproval policy. We developed a logistic regression model to assess risk factors associated with 14-day crude mortality. Propensity score for polymyxin was used to control biases.
Results
Seventy (34%) of 203 patients had infections with at least 1 multidrug-resistant organism isolated from any clinical culture. Polymyxins in monotherapy or in combination therapy were prescribed to 140 of the 203 (69%) patients. The overall 14-day mortality rate was 30%. The 14-day crude mortality was associated with age (adjusted odds ratio [aOR], 1.03; 95% confidence interval [CI], 1.01–1.05; P = .01), SOFA (sepsis-related organ failure assessment) score value (aOR, 1.2; 95% CI, 1.09–1.32; P < .001), CR-GNB infection (aOR, 3.94; 95% CI, 1.53–10.14; P = .005), and time between suspected sepsis and antibiotic administration (aOR, 0.73; 95% CI, .65–.83; P < .001). The empirical use of polymyxins was not associated with decreased crude mortality (aOR, 0.71; 95% CI, .29–1.71; P = .44).
Conclusions
Empirical use of polymyxin for septic patients in a setting with high CR-GNB prevalence was not associated with decreased crude mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil.
- Infection Control Department, Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil.
- Department of Infectious Diseases, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
- Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Zitieren
APA
Bezerra, C. L. P. A. M., Dos Santos, E. L., Oliveira, M. S., Dias, M. B. S., Levin, A. S., Freire, M. P., Boszczowski, I., & Salomão, M. C. (2023). Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad272
Vancouver
Bezerra CLPAM, Dos Santos EL, Oliveira MS, Dias MBS, Levin AS, Freire MP, et al. Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad272
BibTeX
@article{Bezerra2023,
author = {Bezerra, Camila L P A M and Dos Santos, Eusébio L and Oliveira, Maura S and Dias, Maria Beatriz S and Levin, Anna S and Freire, Maristela P and Boszczowski, Icaro and Salomão, Matias C},
title = {Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad272}
}
EUVIMED